Evolution of the Average Target: Moderna, Inc.

Evolution of the Target Price: Moderna, Inc.

Changes in Analyst Recommendations: Moderna, Inc.

daa.otg-lxrDZ050jxx0Z8JXQ1c-oKowFlHnlVd2czO0B8E.yKp3rn2XUj0x_HA2DrATd2R8zfAJIB2E4gQkR3-HNLvQulDedpQJIjnQew~633740effe27d01907b80a7d19088ef4
02:21pm Moderna Shares Rise After Wolfe Research Upgrade MT
06:11am Wolfe Upgrades Moderna to Peer Perform From Underperform MT
08-24 Barclays Adjusts Price Target on Moderna to $125 From $48 MT
08-24 Analyst recommendations: Kimberly-Clark, Palantir, Snap, Crowdstrike, Accenture… Zonebourse
08-21 JPMorgan Adjusts Price Target on Moderna to $77 From $40, Keeps Underweight Rating MT
08-21 Analyst recommendations: Equifax, Medpace Holdings, Applied Materials, PayPal, Moderna… Zonebourse
08-20 UBS Adjusts Moderna Price Target to $150 From $50, Maintains Neutral Rating MT
08-20 Jefferies Adjusts Price Target on Moderna to $150 From $60, Keeps Hold Rating MT
08-20 Piper Sandler Adjusts Price Target on Moderna to $167 From $77, Keeps Overweight Rating MT
08-20 Analyst recommendations: Datadog, Merck, Estee Lauder, Moderna, Target… Zonebourse
08-19 Piper Sandler Adjusts Price Target on Moderna to $167 From $77, Maintains Overweight Rating MT
08-19 BofA Securities Upgrades Moderna to Neutral From Underperform Following Intismeran 'Success', Raises Price Target to $170 From $40 MT
08-19 Goldman Sachs Adjusts Price Target on Moderna to $120 From $67, Keeps Neutral Rating MT
08-19 Moderna and Merck & Co, the day's Wall Street standouts Zonebourse
08-19 William Blair Upgrades Moderna to Outperform From Market Perform MT
08-03 Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says MT
08-03 UBS Raises Moderna Price Target to $50 From $45, Maintains Neutral Rating MT
08-03 Citigroup Adjusts Price Target on Moderna to $60 From $41, Maintain Neutral Rating MT
07-20 Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating MT
07-13 Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating MT
07-08 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says MT
07-08 Morgan Stanley Adjusts Price Target Moderna to $39 From $33, Maintains Equalweight Rating MT
07-07 Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says MT
07-07 BofA Adjusts Price Target on Moderna to $38 From $34, Maintains Underperform Rating MT
07-07 RBC Capital Adjusts Moderna Price Target to $45 From $38, Maintains Sector Perform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-31.12%
+1.44%
-3.37%
+25.13%
+29.67%
+8%
-0.67%
+19.92%
+10.08%
+16.08%
Average +7.52%
Weighted average by Cap. +5.06%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
138.89USD
Average target price
99.82USD
Spread / Average Target
-28.13%
High Price Target
170.00USD
Spread / Highest target
+22.40%
Low Price Target
40.00USD
Spread / Lowest Target
-71.20%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barclays
JPMorgan Chase
UBS
Jefferies & Co.
Piper Sandler
BofA Securities
Goldman Sachs
William Blair & Co.
Citigroup
Morgan Stanley
RBC Capital Markets
Leerink Partners
JEFFERIES Andrew Tsai
Deutsche Bank Securities
Berenberg Bank
Rothschild & Co Redburn
Bernstein
TD Cowen
Wolfe Research
Evercore ISI
DBS Bank
Redburn Atlantic
HSBC
Argus
Baptista Research
BERENBERG Harry Gillis
Brookline Capital Markets
Oppenheimer
Oddo BHF
JPMORGAN Jessica Fye
RBC Luca Issi
Redburn
Canaccord Genuity
Guggenheim
SVB Securities LLC
Cowen
Chardan Research
SVB Leerink
Chardan
J.P. Morgan Chase
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
138.89USD
Average target price
99.82USD
Spread / Average Target
-28.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock
  4. Consensus Moderna, Inc.